Early empirical glycopeptide therapy for patients with methicillin-resistant Staphylococcus aureus bacteraemia: Impact on the outcome

Journal of Antimicrobial Chemotherapy

Volumn 57, Issue 3, 2006, Pages 511-519

  Fang, Chi Tai ^a   Shau, Wen Yi ^b   Hsueh, Po Ren ^a   Chen, Yee Chun ^a   Wang, Jann Tay ^a   Hung, Chien Ching ^a   Huang, Loreen Y L ^c   Chang, Shan Chwen ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Nosocomial infections; Prognosis; Teicoplanin; Vancomycin

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; METRONIDAZOLE; POLYPEPTIDE ANTIBIOTIC AGENT; TEICOPLANIN; VANCOMYCIN;

ADULT; AGED; ARTICLE; BACTEREMIA; BACTERIAL STRAIN; BACTERIUM ISOLATION; BLOOD CULTURE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG SUBSTITUTION; FEMALE; FOLLOW UP; HOSPITAL INFECTION; HUMAN; KAPLAN MEIER METHOD; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORTALITY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OUTCOMES RESEARCH; PROGNOSIS; RETROSPECTIVE STUDY; SEPTIC SHOCK; SKIN MANIFESTATION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TAIWAN;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; BACTEREMIA; DRUG ADMINISTRATION SCHEDULE; HUMANS; METHICILLIN RESISTANCE; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TEICOPLANIN; VANCOMYCIN;

EID: 32644446540     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkl006     Document Type: Article

References (38)

1. Boyce JM, Cookson B, Christiansen K et al. Methicillin-resistant Staphylococcus aureus. Lancet Infect Dis 2005; 5: 653-63.
2. Duckworth G. Controlling methicillin resistant Staphylococcus aureus: time to return to more stringent methods of control in the United Kingdom? BMJ 2003; 327: 1177-8.
3. NINSS report on surgical site infection and hospital-acquired bacteremia. Commun Dis Rep CDR Wkly 2000; 10: 213-6.
4. Pittet D, Wenzel RP. Nosocomial bloodstream infections: Secular trends in rates, mortality, and contribution to total hospital deaths. Arch Intern Med 1995; 155: 1177-84.
5. Edmond MB, Wallace SE, McClish DK et al. Nosocomial bloodstream infections in United States hospitals: A 3-year analysis. Clin Infect Dis 1999; 29: 239-44.
6. Chen ML, Chang SC, Pan HJ et al. Longitudinal analysis of methicillin-resistant Staphylococcus aureus isolates at a teaching hospital in Taiwan. J Formos Med Assoc 1999; 98: 426-32.
7. Hsueh PR, Teng LJ, Chen WH et al. Increasing prevalence of methicillin-resistant Staphylococcus aureus causing nosocomial infections at a university hospital in Taiwan from 1986 to 2001. Antimicrob Agents Chemother 2004; 48: 1361-4.
8. Cosgrove SE, Sakoulas G, Perencevich EN et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: A meta-analysis. Clin Infect Dis 2003; 36: 53-9.
9. Blot SI, Vandewoude KH, Hoste EA et al. Outcome and attributable mortality in critically ill patients with bacteremia involving methicillinsusceptible and methicillin-resistant Staphylococcus aureus. Arch Intern Med 2002; 162: 2229-35.
10. Harbarth S, Rutschmann O, Sudre P et al. Impact of methicillin resistance on the outcome of patients with bacteremia caused by Staphylococcus aureus. Arch Intern Med 1998; 158: 182-9.
11. Romero-Vivas J, Rubio M, Fernandez C et al. Mortality associated with nosocomial bacteremia due to methicillin-resistant Staphylococcus aureus. Clin Infect Dis 1995; 21: 1417-23.
12. Centers for Disease Control and Prevention. Preventing the spread of vancomycin resistance, recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR 1995; 44 (RR12): 1-13.
13. Amyes SGB. Treatment of staphylococcal infection: Prescriptions must be part of a package that includes infection control. BMJ 2005; 330: 976-7.
14. Roghmann MC. Predicting methicillin resistance and the effect of inadequate empiric therapy on survival in patients with Staphylococcus aureus bacteremia. Arch Intern Med 2000; 160: 1001-4.
15. Lodise TP, McKinnon PS, Swiderski L et al. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis 2003; 36: 1418-23.
16. Kim SH, Park WB, Lee KD et al. Outcome of inappropriate initial antimicrobial treatment in patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2004; 54: 489-97.
17. Cordova SP, Heath CH, McGechie DB et al. Methicillin-resistant Staphylococcus aureus bacteraemia in Western Australian teaching hospitals, 1997-1999: Risk factors, outcomes and implications for management. J Hosp Infect 2004; 56: 22-8.
18. Coello R, Glynn JR, Gaspar C et al. Risk factors for developing clinical infection with methicillin-resistant Staphylococcus aureus (MRSA) amongst hospital patients initially only colonized with MRSA. J Hosp Infect 1997; 37: 39-46.
19. Leibovici L, Samra Z, Konigsberger H et al. Long-term survival following bacteremia or fungemia. JAMA 1995; 274: 807-12.
20. Kloos WE, Bannerman TL. Staphylococcus and Micrococcus. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of Clinical Microbiology. 7th edn. Washington, D.C.: ASM Press, 1999; 264-82.
21. National Committee for Clinical Laboratory Standard. Performance Standards for Antimicrobial Disk Susceptibility Tests-4th edition: Approved Standard M2-A6. NCCLS, Villanova, PA, USA, 1990.
22. Tenover FC, Lancaster MV, Hill BC, et al. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol 1998; 36: 1020-7.
23. Hsieh GY, Chen PC, Wang JD. Verification and correction of error for death registration data of the Department of Health R.O.C. between 1980 and 1997. Taiwan J Public Health 2002; 21: 329-38.
24. Knaus WA, Draper EA, Wagner DP et al. APACHE II: A severity of disease classification system. Crit Care Med 1985; 13: 818-29.
25. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20: 864-910.
26. McCabe WR, Jackson GG. Gram-negative bacteremia. Arch Inter Med 1962; 110: 847-64.
27. Lodise TP Jr, McKinnon PS, Rybak M. Prediction model to identify patients with Staphylococcus aureus bacteremia at risk for methicillin resistance. Infect Control Hosp Epidemiol 2003; 24: 655-61.
28. Vardakas KZ, Samonis G, Chrysanthopoulou SA et al. Role of glycopeptides as part of initial empirical treatment of febrile neutropenic patients: a meta-analysis of randomised controlled trials. Lancet Infect Dis 2005; 5: 431-9.
29. Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339: 520-32.
30. Gonzalez C, Rubio M, Romero-Vivas J et al. Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 1999; 29: 1171-7.
31. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991; 115: 674-80.
32. Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug abusers. Antimicrob Agents Chemother 1990; 34: 1227-31.
33. Sakoulas G, Moise-Broder PA, Schentag J et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42: 2398-402.
34. Chang SC, Fang CT, Chen CY et al. In vitro activity of quinupristin/ dalfopristin against common pathogenic bacteria isolated in Taiwan. Diagn Microbiol Infect Dis 1999; 33: 299-303.
35. Fang CT, Chang SC, Chen YC et al. In vitro activity of linezolid against clinical gram-positive bacterial isolates from Taiwan: An area with a high prevalence of antibiotic resistance. Int J Antimicrob Agents 2001; 18: 267-70.
36. Cruciani M, Gatti G, Lazzarini L et al. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 1996; 38: 865-9.
37. Soto J, Sacristan JA, Alsar MJ. Necessity of a loading dose when using vancomycin in critically ill patients. J Antimicrob Chemother 1991; 27: 875.
38. Huletsky A, Giroux R, Rossbach V et al. New real-time PCR assay for rapid detection of methicillin-resistant Staphylococcus aureus directly from specimens containing a mixture of staphylococci. J Clin Microbiol 2004; 42: 1875-84.